ArticleFrontiers in veterinary science2026
PLGA nanoparticles loaded with recombinant antimicrobial protein PIP significantly improves the survival state and pathological damage caused by ETEC O8-induced sepsis in mice.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Peptide-based antimicrobial drugs are promising alternatives to antibiotics owing to their broad-spectrum bactericidal activity and unique pathogen membrane disruption mechanism. Our previous study demonstrated that the recombinant antimicrobial protein PIL22-PBD-2 (PIP) inhibits pathogens and repairs intestinal cell damage Methods: In this study, we developed an oral drug delivery nano-platform composed of PIP and poly(lactic-co-glycolic acid) (PLGA) using the double emulsion solvent evaporation method, and evaluated its therapeutic efficacy in a mouse model of sepsis induced by enterotoxigenic Results: PLGA-PIP nanoparticles were successfully prepared and showed excellent resistance to trypsin degradation as well as good biocompatibility Discussion: These findings demonstrate that PLGA-PIP effectively ameliorates ETEC O8-induced sepsis in mice by enhancing intestinal barrier function, reducing pathogen burden, and inhibiting inflammation. Therefore, PLGA-PIP represents a promising oral antibiotic alternative for the treatment of bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.